TORONTO, ONTARIO--(Marketwired - Jan. 17, 2017) - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company") (TSX VENTURE:VPT) announces that it has filed an application
with Health Canada for approval of the expansion of the VMS™ heart analysis product to include right atrium (RA), left
atrium (LA) and left ventricle (LV) chambers of the heart. The VMS is already licensed in Canada for use for the right
ventricle (RV). This expansion allows the determination of volume and function for all four chambers of the heart using
conventional 2D ultrasound and reduces the need for costly and delayed MRI exams, which is the only other way to get accurate and
reliable measurements.
"I am pleased to report we have successfully built and tested the KBR databases for the RA, LA and LV to yield results
substantially equivalent to gold-standard MRI," stated Dr. George Adams, CEO of Ventripoint. "This will enable patients to
be fully evaluated using 2D ultrasound on each visit and allow for better monitoring of changes in the anatomy and function of
the heart."
Each chamber of the heart is important in understanding how the heart is functioning in the numerous different types of heart
disease. For example, it has been shown that changes in LA function are important in predicting outcomes, which are needed to
properly perform patient monitoring in ischemic heart disease, heart failure, non-ischemic cardiomyopathies, aortic stenosis,
hypertension and atrial fibrillation. The LA size is affected by heart adaptations in a variety of cardiovascular diseases and a
strong predictor of cardiovascular severity and death. The complex shape of the RA makes it difficult to calculate volumes
accurately even using MRI, where a high heart rate causes clinically-relevant errors. Measurement of left and right atrial size
is also important for the management of arrhythmias, valvular and congenital heart disease. The LV is the major pumping
chamber of the heart and is associated with all types of heart disease. The importance of the RV in right-heart diseases has been
well described and the medical literature is increasingly documenting the need for RV analysis in left heart disease as well.
Health Canada usually approves such applications in 30 to 60 days and the Company will begin marketing the product as soon as
it receives the medical device license to do so in Canada.
The Company is preparing submissions for other jurisdictions and will announce when they are submitted.
Forward-Looking Statements:
The information in this release may contain certain forward-looking information. Such information involves known and unknown
risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from
those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information
currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings, actual events may differ materially from current
expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.